MedTrace Logo

Phase 3 Study to Evaluate the Efficacy and Safety of the DW0929 in Patients With Primary Hypercholesterolemia

NCT02390375 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 348

Last updated 2016-10-10

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of the DW0929 in patients with primary hypercholesterolemia

Conditions

Interventions

DRUG

DW-0929

5/10mg

DRUG

DW-0929

10/10mg

DRUG

DW-0929

20/10mg

DRUG

Rosuvastatin

5mg F/U study: DW-0929 5/10mg

DRUG

Rosuvastatin

10mg F/U study: DW-0929 10/10mg

DRUG

Rosuvastatin

20mg F/U study: DW-0929 20/10mg

Sponsors & Collaborators

  • Daewon Pharmaceutical Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
FACTORIAL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-11-30
Primary Completion
2016-04-30
Completion
2016-05-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02390375 on ClinicalTrials.gov